EHA Unplugged

Join us for an interview with Prof Kostas Stamatopoulos, as he shares his personal journey as both a medical doctor and a researcher in hematology and understand how these two activities have always been profoundly linked in his drive to deliver impactful solutions for patients - even though years may pass between a discovery and a change for patients in clinical practice. Prof Stamatopoulos descr...

This podcast episode is derived from the MDS Algorithm on EHA Campus . Check out the MDS Algorithm, which is an expert based tool for healthcare providers, ensuring a structured and evidence-based approach to managing myelodysplastic syndromes. In this episode, our host Prof Kirsten Grønbæk from University of Copenhagen, discusses the management of high-risk MDS with Prof Katharina Götze from Tech...

In this episode on recent insights about metabolism of the hematopoietic stem cells (HSCs), Dr Krzysztof Szade from Jagellonian University in Krakow, Poland, discusses HSPc in health, aging and malignancy. This podcast recaps the findings that aim to elucidate the metabolic requirements of HSCs at different stages of aging. Listen to Dr Szade summarize the data on how heme oxygenase-1 (HO-1) influ...

This podcast episode highlights the need to use innovative clinical trial designs in the era of increasingly personalized medicine in hematology. Listen to Dr Jurjen Versluis from Erasmus Medical Center in Rotterdam, the Netherlands, discuss his research on this topic. As the amount of novel targeted drugs is increasing, and treatments lead to increasingly better survival outcomes, we need to thin...

As knowledge about hereditary hematological malignancies (HHMs) increases, so do the options for better management of these diseases. Please join us in this podcast to hear Dr Kiran Tawana from Addenbrooke’s Hospital in Cambridge, UK, share her insights on this topic. HHMs are syndromes where two or more cases of cytopenia and hematological malignancy (typically MDS/AML) occur within the same fami...

In this podcast, Prof Thorsten Zenz from University Hospital in Zurich, Switzerland, discusses the current approaches to treatment of relapsed hairy cell leukemia (HCL). Based on his personal journey as a hematologist interested in precision oncology, prof. Zenz summarizes the years of accumulating data and clinical experience to explain the treatment approach he often uses for his patients. Thank...

In this episode of EHA Unplugged, Prof Kirsten Grønbæk and our guests Prof Yelena Ginzburg and Prof Amit Verma discuss iron metabolism and its role in erythropoiesis in MDS. The experts share their views on the management of iron overload in the transfusion-dependent patients with MDS, as they acknowledge that it poses a real challenge in their clinical practice. Starting from the criteria used to...

In this podcast, Dr Elisabeth Schorb from University Medical Center in Freiburg, Germany, discusses the first-line treatment of primary central nervous system lymphoma (PCNSL), which has seen tremendous advances in the last years. PCNSL is a rare condition, and because of its location prompt diagnosis and timely treatment are of the essence. As for other hematological diseases, treatment of PCNSL...

With the increasing scrutiny of healthcare pathways for women, this podcast provides a timely plea by Dr Michelle Lavin from St. James’s Hospital in Dublin, Ireland, to optimize global care for women with von Willebrand disease (VWD). In this podcast, Dr Lavin gives a passionate appeal for more international collaboration and increased awareness to improve care for women and girls suffering from b...

In this lecture from EHA2024, Prof Domenico Girelli from University of Verona, Italy, discusses the complex relationship between iron metabolism and infection. As an essential element for physiology of all living organisms, iron is involved in many vital processes, including our immune responses to infections. Since the pathogens themselves also depend on iron to survive, the resulting host/pathog...

Join us for an insightful lecture by Prof Maria Teresa Voso from University of Rome Tor Vergata in Italy, as she discusses the advances in the treatment of a rare subtype of AML, the acute promyelocytic leukemia (APL). As the PML::RARA rearrangement, resulting in a fusion protein that disrupts retinoic acid signaling and PML function, is the hallmark driver of APL, it is used as target for APL tre...

Join us for this engaging debate on the future of acquired TTP (aTTP) treatment chaired by Dr. Eleni Gavriilaki from Aristotle University of Thessaloniki in Greece. This discussion features Prof. Marie Scully from University College London Hospital in UK and Prof. Paul Coppo from Saint-Antoine Hospital in Paris, France. The debate centers on whether therapeutic plasma exchange (PEX) combined with...

Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here.    Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnos...

Tune in to EHA Unplugged for an engaging chat with Professor Lars Bullinger from Charité University Medicine, Berlin. He'll break down the latest in myeloid disease classification, discussing how new genetic insights are transforming our understanding of MDS and AML. Discover the hurdles clinicians face, the promise of innovative treatments, and the future of preventive medicine, including the imp...

Join us for an insightful episode featuring Prof David Rees from King’s College Hospital in London as he discusses screening practices for Sickle Cell disease (SCD). Hosted by Dr Sarah de Vlieger, this discussion explores both antenatal and neonatal screening practices for Sickle Cell disease. The conversation begins with an examination of antenatal screening challenges, comparing various techniqu...

Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future. The conversation highlights how climate change alters aspects of hem...

Join us in this podcast episode, exploring with Prof Matteo Della Porta (Humanitas Research Hospital, Milano, Italy) the emerging role of "synthetic patients" in hematological clinical trials. Innovative generative artificial intelligence models allow today to create synthetic data set based on real patients, suitable to be used as control groups in clinical trials, helping in the identification o...

Join us for an insightful interview with Prof Bruno Paiva from Clinical University of Navarra in Pamplona, Spain, as he and our host Dr. Isabel Olivera-Martinez, discuss the latest technical approaches to improving monitoring, risk stratification and differential diagnosis of patients with monoclonal gammopathies including MGUS (monoclonal gammopathy of unknown significance), smoldering myeloma an...

Join us for an interview with Prof Ivo Touw, who has received the prestigious EHA David Grimwade Award for his contributions to the field of hematology research. Prof Touw and his research group focus on molecular signaling in leukemia predisposition syndromes, such as severe congenital neutropenia (SCN). They have described the dysfunction of the membrane receptor for the growth factor G-CSF and...

Join us for an insightful interview with Professor Saskia Middeldorp from Radboud University Medical Center in Nijmegen, The Netherlands, as she and our host Dr. Isabel Olivera-Martinez, discuss the medical and ethical challenges of conducting randomized clinical trials to prevent venous thromboembolism (VTE) during pregnancy.  VTE is a leading cause of maternal morbidity and mortality, and poses...

Join us for an insightful interview with Professor Frank Leebeek from Erasmus University in Rotterdam, The Netherlands, as he discusses together with our host, Dr. Isabel Olivera-Martinez, the potential of gene therapy to free hemophilia patients from the standard coagulation factor replacement therapy. Prof. Leebeek explains how gene therapy for hemophilia is carried out and differentiates the cu...

In this podcast episode, we will explore the application of artificial intelligence to morphological diagnosis in hematology. Listening to our host, Dr Mahesh Prahladan (University of Suffolk, UK) you will learn how innovative machine learning and deep learning models have led to the development of AI systems that have been applied in various areas of hematology, including digital pathology.   As...

Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain), the first academic centre to achieve the authorisation to treat patients with a CAR T therapy developed 100% by academia.  Prof Delgado discusses the complexities of obtaining regulatory approval for CAR T-cell therapy,  under the EU regulation for advanced therapy medicinal products (ATMPs). In th...

Join us for this podcast discussing the promises and challenges of academic and point-of-care CAR T-cell manufacturing with Dr Anna Sureda, president of EBMT ( European Society for Blood and Marrow Transplantation ).  Dr Sureda provides her expert point of view on how CAR T-cells produced in academic centres may enhance patient access to CAR-T treatment, reducing costs and turnround times for prod...

Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain) as he explains the intricate process of CAR T-cell therapy. In this episode, we cover the key steps involved in CAR T, such as patient identification, apheresis, manufacturing, cell infusion and managing post-infusion related toxicities. Prof Delgado offers expert insights on each component of this...